TC BioPharm (Holdings) (TC BioPharm (Holdings)) ROCE % : -413.18% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TC BioPharm (Holdings)'s annualized ROCE % for the quarter that ended in Mar. 2024 was -413.18%.

TC BioPharm (Holdings) ROCE % Historical Data

The historical data trend for TC BioPharm (Holdings)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) ROCE % Chart

TC BioPharm (Holdings) Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-105.79

-138.08

-221.99

TC BioPharm (Holdings) Quarterly Data
	Dec19	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial							-	-780.25	431.94	-	-413.18

TC BioPharm (Holdings) ROCE % Calculation

TC BioPharm (Holdings)'s annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.751	/	( ( (13.754 - 11.162)	+	(11.306 - 6.014) )	/ 2 )
	=	-8.751	/	( (2.592	+	5.292)	/ 2 )
	=	-8.751	/	3.942
	=	-221.99 %

TC BioPharm (Holdings)'s ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-17.496	/	( ( (11.306 - 6.014)	+	(9.23 - 6.053) )	/ 2 )
	=	-17.496	/	( ( 5.292	+	3.177 )	/ 2 )
	=	-17.496	/	4.2345
	=	-413.18 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

TC BioPharm (Holdings) (NAS:TCBP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TC BioPharm (Holdings) ROCE % Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

T0U:Germany

Address

Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR

Website

https://www.tcbiopharm.com

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Executives

Renaissance Capital Partners Ltd	10 percent owner	42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall	10 percent owner	C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD